Connect with us

Spread & Containment

Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675%

Penny stocks to buy according to analysts.
The post Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675% appeared first on Penny Stocks…

Published

on

One of the best parts about penny stocks is that there are so many of them right now. Similar to what we saw during the pandemic, hundreds of companies had fallen victim to the broad sector sell-offs this year. It hasn’t only been “start-ups” either. Plenty of household name companies are trading below the $5 threshold.

Taking OTC penny stocks out of the equation still leaves hundreds of Nasdaq and NYSE listed companies trading at low prices. As of June 9th’s premarket session, more than 1,700 companies are sitting at $5 or less. This is, by far, one of the most significant counts of cheap stocks available to traders in the stock market today.

What does this mean for investors? For starters, it will likely introduce plenty of them to this volatile world of penny stocks. Some of the most recognizable companies, many a part of multi-million dollar SPAC deals in 2021, are facing the music of the 2022 stock market crash. But there’s hope, at least for traders right now. Penny stocks have offered up some of the most considerable potential for short-term gains compared to most other asset classes. Today we look at a few that analysts have become bullish on. They’ve even gone as far as setting price targets of up to 675%.

Penny Stocks To Watch

  1. Wejo Group Limited (NASDAQ: WEJO)
  2. ContraFect Corp (NASDAQ: CFRX)
  3. Bluejay Diagnostics Inc. (NASDAQ: BJDX)

1. Wejo Group Limited (NASDAQ: WEJO) $5 Target

It’s not often you see penny stock companies mixing with market leaders. However, it isn’t entirely out of the question either. Wejo Group is in the spotlight this week for exactly that reason.

The cloud and software analytics company specializes in connected, autonomous, electric vehicle data and just extended collaboration with a well-known tech company. Microsoft (NASDAQ: MSFT) and Wejo will expand an existing deal with Microsoft Maps. The agreement aims to facilitate Microsoft’s ability to gain real-time insight from Wejo data and improve mapping capabilities overall.

While no financial specifics of the expansion were detailed in today’s update, traders have reacted bullishly during premarket trading. What’s more, WEJO stock will be joining the Russell 3000 Index on June 27th, which could be something traders are following right now.

[Read More] What to Know About Buying Penny Stocks on June 9th

WEJO Stock Forecast

What do analysts think about WEJO stock? Several firms are covering the penny stock. However, the latest rating from Baird puts a bullish outlook with an Outperform rating. There’s also a $5 target, which sits 123% higher than its closing price on June 8th.

2. ContraFect Corp (NASDAQ: CFRX) $9 Target

The clinical-stage biotech company, ContraFect has gained significant momentum this year. Most of the focus has been on its pipeline candidates, namely its direct lytic agents (DLAs) development. In an update earlier this week, ContraFect announced vital presentations at the upcoming ASM Microbe 2022 Conference this weekend.

ContraFect presents two posters at the conference that cover its Breakthrough Therapy designated candidate, exebacase. The treatment is in a pivotal Phase 3 study right now. It has previously shown bactericidal activity against Staph aureus (MRSA).

Looking ahead, July could be an important month for the company. In its first-quarter update, CEO Roger Pomerantz, M.D., said, “We turn our attention to the interim futility analysis, which…will enable the Data Safety Monitoring Board, or DSMB, to assess the probability for exebacase to achieve superiority on the primary efficacy endpoint of the study. Once the data necessary for this analysis is collected, processed, and delivered to the DSMB, we will be informed of their recommendation regarding study continuation. We expect this to occur during the first week of July.”

If the response is positive, the company said it would move toward a potential Biologics License Application submission.

CFRX Stock Forecast

Several analyst firms are covering CFRX stock. The most recent update from SVB Leerink places an Outperform rating and a $9 target on the stock. Though this target is down from the previous $14 PT, it remains 130% higher than June 8th’s closing price.

penny stocks to buy now analyst forecast ContraFect Corp CFRX stock chart

3. Bluejay Diagnostics Inc. (NASDAQ: BJDX) $10 Target

Last on this list of penny stocks is one of Thursday’s high-flyers, Bluejay Diagnostics. Biotech stocks, in general, haven’t been in the best favor of the stock market this year. Look at the Nasdaq Biotech ETF (NASDAQ: IBB), and you’ll see what I’m talking about. The IBB dropped as much as 30% this year in the wake of the stock market crash.

Regardless, the trend hasn’t stopped short-term breakouts in different pockets of the sector. Bluejay Diagnostics caught a strong surge of momentum this week, thanks to milestone news. The company announced that the FDA agreed to consider its plan to pursue a De Novo submission for its Symphony IL-6 Test. This test is under development for near-patient testing to determine the proper care and monitoring processes.

Adding to the excitement were comments from CEO Neil Dey giving a rough timeline of a potential marketing application submission to the FDA. Dey said, “This confirms our belief that the Bluejay Symphony IL-6 Test has the potential to provide an innovative solution to the market. Bluejay continues to advance the Symphony IL-6 Test towards the Company’s anticipated marketing application with the FDA, expected by year-end 2022.”

BJDX Stock Forecast

What do analysts think about BJDX stock? If analysts at Dawson James are to be believed, there could be much more to look out for with this penny stock. That’s not only based on the firm’s Buy rating but also a price target 675% higher than Wednesday’s closing price. Dawson James has its target set at $10 right now.

penny stocks to buy now analyst forecast Bluejay Diagnostics BJDX stock chart

Best Penny Stocks To Buy

Analyst ratings can be great to use as part of your overall due diligence process. However, they shouldn’t be the only tool to use. News, filings, and even retail sentiment can play a large part in different stock market trends. For that reason, it’s important to dive deeper and then determine if certain stocks should earn a place on your watch list or not. Today we looked at 3 with optimistic outlooks from analysts. Will they become the next round of top penny stocks to buy in June, or did analysts miss the mark? Let us know in the comments section.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Inside The Secret Government Meeting On COVID-19 Natural Immunity

Inside The Secret Government Meeting On COVID-19 Natural Immunity

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Four of…

Published

on

Inside The Secret Government Meeting On COVID-19 Natural Immunity

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Four of the highest ranking U.S. health officials—including Dr. Anthony Fauci—met in secret to discuss whether or not naturally immune people should be exempt from getting COVID-19 vaccines, The Epoch Times can reveal.

National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci during a Senate hearing in Washington on May 17, 2022. (Shawn Thew/Pool/AFP via Getty Images)

The officials brought in four outside experts to discuss whether the protection gained after recovering from COVID-19—known as natural immunity—should count as one or more vaccine doses.

“There was interest in several people in the administration in hearing basically the opinions of four immunologists in terms of what we thought about … natural infection as contributing to protection against moderate to severe disease, and to what extent that should influence dosing,” Dr. Paul Offit, one of the experts, told The Epoch Times.

Offit and another expert took the position that the naturally immune need fewer doses. The other two experts argued natural immunity shouldn’t count as anything.

The discussion did not lead to a change in U.S. vaccination policy, which has never acknowledged post-infection protection. Fauci and the other U.S. officials who heard from the experts have repeatedly downplayed that protection, claiming that it is inferior to vaccine-bestowed immunity. Most studies on the subject indicate the opposite.

The meeting, held in October 2021, was briefly discussed before on a podcast. The Epoch Times has independently confirmed the meeting took place, identified all of the participants, and uncovered other key details.

Dr. Jay Bhattacharya, a professor of medicine at Stanford University who did not participate in the meeting, criticized how such a consequential discussion took place behind closed doors with only a few people present.

“It was a really impactful decision that they made in private with a very small number of people involved. And they reached the wrong decision,” Bhattacharya told The Epoch Times.

An email obtained by The Epoch Times shows Dr. Vivek Murthy contacting colleagues to arrange the meeting. (The Epoch Times)

The Participants

From the government:

  • Fauci, the head of the U.S. National Institute of Allergy and Infectious Diseases and the chief medical adviser to President Joe Biden until the end of 2022
  • Dr. Vivek Murthy, the U.S. surgeon general
  • Dr. Rochelle Walensky, the head of U.S. Centers for Disease Control and Prevention (CDC)
  • Dr. Francis Collins, head of the U.S. National Institutes of Health, which includes the National Institute of Allergy and Infectious Diseases, until December 2021
  • Dr. Bechara Choucair, the White House vaccine coordinator until November 2021

From outside the government:

  • Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and an adviser to the U.S. Food and Drug Administration on vaccines
  • Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota and a former member of Biden’s COVID-19 advisory board
  • Akiko Iwasaki, professor of immunobiology and molecular, cellular, and developmental biology at Yale University
  • Dr. Peter Hotez, co-director of Texas Children’s Hospital Center for Vaccine Development and dean of the Baylor College of Medicine’s School of Tropical Medicine

Fauci and Murthy decided to hold the meeting, according to emails The Epoch Times obtained.

“Would you be available tonight from 9-9:30 for a call with a few other scientific colleagues on infection-induced immunity? Tony and I just discussed and were hoping to do this sooner rather than later if possible,” Murthy wrote in one missive to Fauci, Walensky, and Collins.

All three quickly said they could make it.

Walensky asked who would be there.

Murthy listed the participants. “I think you know all of them right?” he said.

Walensky said she knew all but one person. “Sounds like a good crew,” she added.

From top left, clockwise: Dr. Vivek Murthy, Dr. Francis Collins, Dr. Anthony Fauci, and Dr. Rochelle Walensky. (Getty Images)

‘Clear Benefit’

During the meeting, Offit put forth his position—that natural immunity should count as two doses.

At the time, the CDC recommended three shots—a two-dose primary series and a booster—for many Americans 18 and older, soon expanding that advice to all adults, even though trials of the boosters only analyzed immunogenicity and efficacy among those without evidence of prior infection.

Research indicated that natural immunity was long-lasting and superior to vaccination. On the other hand, the CDC published a paper in its quasi-journal that concluded vaccination was better.

Osterholm sided with Offit, but thought that having recovered from COVID-19 should only count as a single dose.

“I added my voice at the meeting to count an infection as equivalent to a dose of vaccine! I’ve always believed hybrid immunity likely provides the most protection,” Osterholm told The Epoch Times via email.

Hybrid immunity refers to getting a vaccine after recovering from COVID-19.

Some papers have found vaccination after recovery boosts antibodies, which are believed to be a correlate of protection. Other research has shown that the naturally immune have a higher risk of side effects than those who haven’t recovered from infection. Some experts believe the risk is worth the benefit but others do not.

Hotez and Iwasaki, meanwhile, made the case that natural immunity should not count as any dose—as has been the case in virtually the entire United States since the COVID-19 vaccines were first rolled out.

Iwasaki referred to a British preprint study, soon after published in Nature, that concluded, based on survey data, that the protection from the Pfizer and AstraZeneca vaccines was heightened among people with evidence of prior infection. She also noted a study she worked on that found the naturally immune had higher antibody titers than the vaccinated, but that the vaccinated “reached comparable levels of neutralization responses to the ancestral strain after the second vaccine dose.” The researchers also discovered T cells—thought to protect against severe illness—were boosted by vaccination.

There’s a “clear benefit” to boosting regardless of prior infection, Iwasaki, who has since received more than $2 million in grants from the National Institutes of Health (NIH), told participants after the meeting in an email obtained by The Epoch Times. Hotez received $789,000 in grants from the NIH in fiscal year 2020, and has received other grants totaling millions in previous years. Offit, who co-invented the rotavirus vaccine, received $3.5 million in NIH grants from 1985 through 2004.

Hotez declined interview requests through a spokesperson. Iwasaki did not respond to requests for comment.

No participants represented experts like Bhattacharya who say that the naturally immune generally don’t need any doses at all.

In an email obtained by The Epoch Times, Akiko Iwasaki wrote to other meeting participants shortly after the meeting ended. (The Epoch Times)

Public Statements

In public, Hotez repeatedly portrayed natural immunity as worse than vaccination, including citing the widely criticized CDC paper, which drew from just two months of testing in a single state.

In one post on Twitter on Oct. 29, 2021, he referred to another CDC study, which concluded that the naturally immune were five times as likely to test positive compared to vaccinated people with no prior infection, and stated: “Still more evidence, this time from @CDCMMWR showing that vaccine-induced immunity is way better than infection and recovery, what some call weirdly ‘natural immunity’. The antivaccine and far right groups go ballistic, but it’s the reality.”

That same day, the CDC issued a “science brief” that detailed the agency’s position on natural immunity versus the protection from vaccines. The brief, which has never been updated, says that available evidence shows both the vaccinated and naturally immune “have a low risk of subsequent infection for at least 6 months” but that “the body of evidence for infection-induced immunity is more limited than that for vaccine-induced immunity.”

Evidence shows that vaccination after infection, or hybrid immunity, “significantly enhances protection and further reduces risk of reinfection” and is the foundation of the CDC’s recommendations, the agency said.

Several months later, the CDC acknowledged that natural immunity was superior to vaccination against the Delta variant, which was displaced in late 2021 by Omicron. The CDC, which has made misleading representations before on the evidence supporting vaccination of the naturally immune, did not respond to a request for comment regarding whether the agency will ever update the brief.

Iwasaki had initially been open to curbing the number of doses for the naturally immune—”I think this supports the idea of just giving one dose to people who had covid19,” she said in response to one Twitter post in early 2021, which is restricted from view—but later came to argue that each person who is infected has a different immune response, and that the natural immunity, even if strong initially, wanes over time.

Osterholm has knocked people who claim natural immunity is weak or non-existent, but has also claimed that vaccine-bestowed immunity is better. Osterholm also changed the stance he took in the meeting just several months later, saying in February 2022 that “we’ve got to make three doses the actual standard” while also “trying to understand what kind of immunity we get from a previous infection.”

Offit has been the leading critic on the Vaccines and Related Biological Products Advisory Committee, which advises U.S. regulators on vaccines, over their authorizations of COVID-19 boosters. Offit has said boosters are unnecessary for the young and healthy because they don’t add much to the primary series. He also criticized regulators for authorizing updated shots without consulting the committee and absent clinical data. Two of the top U.S. Food and Drug Administration (FDA) officials resigned over the booster push. No FDA officials were listed on invitations to the secret meeting on natural immunity.

Fauci and Walensky Downplay Natural Immunity

Fauci and Walensky, two of the most visible U.S. health officials during the pandemic, have repeatedly downplayed natural immunity.

Fauci, who said in an email in March 2020 that he assumed there would be “substantial immunity post infection,” would say later that natural immunity was real but that the durability was uncertain. He noted the studies finding higher antibody levels from hybrid immunity.

In September 2021, months after claiming that vaccinated people “can feel safe that they are not going to get infected,” Fauci said that he did not have “a really firm answer” on whether the naturally immune should get vaccinated.

“It is conceivable that you got infected, you’re protected—but you may not be protected for an indefinite period of time,” Fauci said on CNN when pressed on the issue. “So I think that is something that we need to sit down and discuss seriously.”

After the meeting, Fauci would say that natural immunity and vaccine-bestowed immunity both wane, and that people should get vaccinated regardless of prior infection to boost their protection.

Walensky, before she became CDC director, signed a document called the John Snow Memorandum in response to the Great Barrington Declaration, which Bhattacharya coauthored. The declaration called for focused protection of the elderly and otherwise infirm, stating, “The most compassionate approach that balances the risks and benefits of reaching herd immunity, is to allow those who are at minimal risk of death to live their lives normally to build up immunity to the virus through natural infection, while better protecting those who are at highest risk.”

The memorandum, in contrast, said there was “no evidence for lasting protective immunity to SARS-CoV-2 following natural infection” and supported the harsh lockdown measures that had been imposed in the United States and elsewhere.

In March 2021, after becoming director, Walensky released recommendations that the naturally immune get vaccinated, noting that there was “substantial durability” of protection six months after infection but that “rare cases of reinfection” had been reported.

Walensky hyped the CDC study on natural immunity in August 2021, and the second study in October 2021. But when the third paper came out concluding natural immunity was superior, she did not issue a statement. Walensky later told a blog that the study found natural immunity provided strong protection, “perhaps even more so than those who had been vaccinated and not yet boosted.”

But, because it came before Omicron, she said, “it’s not entirely clear how that protection works in the context of Omicron and boosting.”

Walensky, Murthy, and Collins did not respond to requests for interviews. Fauci, who stepped down from his positions in late 2022, could not be reached.

Murthy and Collins also portrayed natural immunity as inferior. “From the studies about natural immunity, we are seeing more and more data that tells us that while you get some protection from natural infection, it’s not nearly as strong as what you get from the vaccine,” Murthy said on CNN about two months before the meeting. Collins, in a series of blog posts, highlighted the studies showing higher antibody levels after vaccination and urged people to get vaccinated. He also voiced support for vaccine mandates.

Read more here...

Tyler Durden Thu, 02/02/2023 - 21:10

Read More

Continue Reading

Spread & Containment

New sensor enables ‘smart diapers,’ range of other health monitors

UNIVERSITY PARK, Pa. — Waaahhh! While babies have a natural mechanism for alerting their parents that they need a diaper change, a new sensor developed…

Published

on

UNIVERSITY PARK, Pa. — Waaahhh! While babies have a natural mechanism for alerting their parents that they need a diaper change, a new sensor developed by researchers at Penn State could help workers in daycares, hospitals and other settings provide more immediate care to their charges.

Credit: Huanyu “Larry” Cheng/Penn State

UNIVERSITY PARK, Pa. — Waaahhh! While babies have a natural mechanism for alerting their parents that they need a diaper change, a new sensor developed by researchers at Penn State could help workers in daycares, hospitals and other settings provide more immediate care to their charges.

The new sensor — so cheap and simple to produce that it can be hand-drawn with a pencil onto paper treated with sodium chloride — could clear the way for wearable, self-powered health monitors for use not only in “smart diapers” but also to predict major health concerns like cardiac arrest and pneumonia.

“Our team has been focused on developing devices that can capture vital information for human health,” said Huanyu “Larry” Cheng, the James L. Henderson, Jr. Memorial Associate Professor of Engineering Science and Mechanics at Penn State. “The goal is early prediction for disease conditions and health situations, to spot problems before it is too late.”

Cheng is the lead author on a new study, published in the journal Nano Letters, which describes the design and fabrication process for a reliable, hand-drawn electrode sensor. The sensor is created using a pencil, drawn on paper treated with a sodium chloride solution. The hydration sensor is highly sensitive to changes in humidity and provides accurate readings over a wide range of relative humidity levels, from 5.6% to 90%.

Research into wearable sensors has been gaining momentum because of their wide-ranging applications in medical health, disaster warning and military defense, Cheng explained. Flexible humidity sensors have become increasingly necessary in health care, for uses such as respiratory monitoring and skin humidity detection, but it is still challenging to achieve high sensitivity and easy disposal with simple, low-cost fabrication processes, he added.

“We wanted to develop something low-cost that people would understand how to make and use — and you can’t get more accessible than pencil and paper,” said Li Yang, professor in the School of Artificial Intelligence at China’s Hebei University of Technology. “You don’t need to have some piece of multi-million-dollar equipment for fabrication. You just need to be able to draw within the lines of a pre-drawn electrode on a treated piece of paper. It can be done simply and quickly.”

The device takes advantage of the way paper naturally reacts to changes in humidity and uses the graphite in the pencil to interact with water molecules and the sodium chloride solution. As water molecules are absorbed by the paper, the solution becomes ionized and electrons begin to flow to the graphite in the pencil, setting off the sensor, which detects those changes in humidity in the environment and sends a signal to a smartphone, which displays and records the data.

Essentially, drawing on the pre-treated paper within pre-treated lines creates a miniaturized paper circuit board. The paper can be connected to a computer with copper wires and conductive silver paste to act as an environmental humidity detector. For wireless application, such as “smart diapers” and mask-based respiration monitoring, the drawing is connected to a tiny lithium battery which powers data transmission to a smartphone via Bluetooth.

For the respiration monitor, the team drew the electrode directly on a solution-treated face mask. The sensor easily differentiated mouth breathing from nose breathing and was able to classify three breathing states: deep, regular and rapid. Cheng explained that the data collected could be used to detect the onset of various disease conditions, such as respiratory arrest and shortness of breath and provide opportunities in the smart internet of things and telemedicine.

He added that respiratory rate is a fundamental vital sign and research has shown it to be an early indicator of a variety of pathological conditions such as cardiac events, pneumonia and clinical deterioration. It can also indicate emotional stressors like cognitive load, heat, cold, physical effort and exercise-induced fatigue.

Compared with breath, the human skin exhibits a smaller change in humidity, but the researchers were still able to detect changes using their pencil-on-paper humidity sensor, even after test subjects applied lotion or exercised. Skin is the body’s largest organ, Cheng explained, so if it is not processing moisture correctly, that could indicate that some other health issue is going on.

“Different types of disease conditions result in different rates of water loss on our skin,” he said. “The skin will function differently based on those underlying conditions, which we will be able to flag and possibly characterize using the sensor.”

The team also integrated four humidity sensors between the absorbent layers of a diaper to create a “smart diaper,” capable of detecting wetness and alerting for a change.

“That application was actually born out of personal experience,” said Cheng, who is the father of two young children. “There’s no easy way to know how wet is wet, and that information could be really valuable for parents. The sensor can provide data in the short-term, to alert for diaper changes, but also in the long-term, to show patterns that can inform parents about the overall health of their child.”

The applications of the humidity sensor go beyond “smart diapers” and monitoring for respiration and perspiration, Cheng explained. The team also deployed the sensor as a noncontact switch, which could sense the humidity changes in the air from the presence of a finger without the finger touching the sensor. The team used the noncontact switch to operate a small-scale elevator, play a keyboard and light up an LED array.

“The atoms on the finger don’t need to touch the button, they only need to be near the surface to diffuse the water molecules and trigger the signal,” Cheng said. “When we think about what we learned from the pandemic about the need to limit the body’s contact with shared surfaces, a sensor like this could be an important tool to stop potential contamination.”

Other authors on the study are Penn State doctoral candidate Ankan Dutta as well as Guangyu Niu, Zihan Wang, Ye Xue, Jiayi Yan, Xue Chen, Ya Wang, Chaosai Liu, Shuaijie Du Langang Guo of the Hebei University of Technology. Peng Zhou of Tianjin Tianzhong Yimai Technology Development Co. Ltd. also contributed to the research.

Cheng’s work was funded by the National Institutes of Health, the National Science Foundation and Penn State.


Read More

Continue Reading

International

Adani Contagion Spreads As Citi Halts Margin Loans On Debt

Adani Contagion Spreads As Citi Halts Margin Loans On Debt

Indian billionaire Gautam Adani’s corporate empire is crumbling. A deeper selloff…

Published

on

Adani Contagion Spreads As Citi Halts Margin Loans On Debt

Indian billionaire Gautam Adani's corporate empire is crumbling. A deeper selloff forced Adani Enterprises Ltd. to pull a stock sale in the final minute. Two banks have rejected bonds tied to Adani companies as collateral for client trades. And the turmoil has pushed MSCI India Index to the brink of a technical correction. 

Adani Enterprises plunged 27% on Thursday in Mumbai trading after it was revealed late Wednesday that it abandoned a $2.4 billion follow-on share sale. Today's losses added to a 28% tumble in the previous session.

The decision to pull the share offering comes as more than $100 billion in market cap has been wiped out in Adani group's stocks following a scathing report from Hindenburg Research last Tuesday. Dollar bonds tied to the companies are also plunging into the distressed territory, raising the risk of default. 

Yesterday, Bloomberg reported that Credit Suisse designated a zero lending value for bonds sold by Adani Ports and Special Economic Zone, Adani Green Energy, and Adani Electricity Mumbai. Now Citi's wealth management arm has done the same. 

The meltdown in Adani shares has significant implications for Indian stocks:

"This is potentially a bigger problem for Indian equities, which have done so well during the pandemic as China pursued its Covid Zero policy."

"The long-term ramifications could be quite negative," said Peter Garnry, head of equity strategy at Saxo Bank A/S in Hellerup, Denmark. 

Bloomberg added: 

The implosion of the Adani companies, which accounted for almost one out of every $10 invested in Indian stocks at the group's peak in September, has provided a catalyst for investors complaining about the nation's expensive valuations to trim their holdings. The fallout is likely to make it harder for other Indian corporations to raise funds, put them under increased regulatory scrutiny, while also testing the faith voters have in Prime Minister Narendra Modi.

The turmoil has helped push MSCI India Index to the brink of a technical correction. 

Meanwhile, global funds have yanked a net $2 billion out of Indian equities in the three days through Tuesday. Funds are selling now, and asking questions later. 

"The Adani-related headlines are generating a high level of negative attention, which could dampen investor appetite for Indian stocks," said Jian Shi Cortesi, who manages China and Asia equity funds at GAM Investment Management in Zurich.

One major risk we see is the deterioration in access to financing for Adani companies, some of which are highly leveraged. 

Even after the latest slide in Adani group shares, Bloomberg Intelligence's Nitin Chanduka believes there is more downside ahead. 

Tyler Durden Thu, 02/02/2023 - 08:55

Read More

Continue Reading

Trending